Hekking et al., 2018 - Google Patents
Pathway discovery using transcriptomic profiles in adult-onset severe asthmaHekking et al., 2018
View HTML- Document ID
- 2324420587460975370
- Author
- Hekking P
- Loza M
- Pavlidis S
- De Meulder B
- Lefaudeux D
- Baribaud F
- Auffray C
- Wagener A
- Ir P
- Ir R
- Bansal A
- Sousa A
- Bates S
- Pandis Y
- Fleming L
- Shaw D
- Fowler S
- Guo Y
- Meiser A
- Sun K
- Corfield J
- Howarth P
- Bel E
- Adcock I
- Chung K
- Djukanovic R
- Sterk P
- Adcock I
- Ahmed H
- Auffray C
- Bakke P
- Bansal A
- Baribaud F
- Bates S
- Bel E
- Bigler J
- Bisgaard H
- Boedigheimer M
- Bønnelykke K
- Brandsma J
- Brinkman P
- Bucchioni E
- Burg D
- Bush A
- Caruso M
- Chaiboonchoe A
- Chanez P
- Chung F
- Compton C
- Corfield J
- D'Amico A
- Dahlen S
- De Meulder B
- Djukanovic R
- Erpenbeck V
- Erzen D
- Fichtner K
- Fitch N
- Fleming L
- Formaggio E
- Fowler S
- Frey U
- Gahlemann M
- Geiser T
- Hashimoto S
- Haughney J
- Hedlin G
- Hekking P
- Higenbottam T
- Hohlfeld J
- Holweg C
- Horváth I
- Howarth P
- James A
- Knowles R
- Krug N
- Lefaudeux D
- Loza M
- Lutter R
- Manta A
- Masefield S
- Matthews J
- Mazein A
- Meiser A
- Middelveld R
- Miralpeix M
- Mores N
- Murray C
- Musial J
- Myles D
- Pahus L
- Pandis I
- Pavlidis S
- Powel P
- Praticò G
- Valls M
- Rao N
- Riley J
- Roberts A
- Roberts G
- Rowe A
- Sandström T
- Seibold W
- Selby A
- Shaw D
- Sigmund R
- Singer F
- Skipp P
- Sousa A
- Sterk P
- Sun K
- Thornton B
- van Aalderen W
- van Geest M
- Vestbo J
- Vissing N
- Wagener A
- Wagers S
- Weiszhart Z
- Wheelock C
- Wilson S
- Publication year
- Publication venue
- Journal of Allergy and Clinical Immunology
External Links
Snippet
Background Adult-onset severe asthma is characterized by highly symptomatic disease despite high-intensity asthma treatments. Understanding of the underlying pathways of this heterogeneous disease is needed for the development of targeted treatments. Gene set …
- 208000006673 Asthma 0 title abstract description 192
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane, progesterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/12—Pulmonary diseases
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/52—Assays involving cytokines
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Hekking et al. | Pathway discovery using transcriptomic profiles in adult-onset severe asthma | |
| Gauthier et al. | Evolving concepts of asthma | |
| Chung et al. | International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma | |
| Jia et al. | IL-13+ type 2 innate lymphoid cells correlate with asthma control status and treatment response | |
| Kim et al. | Asthma biomarkers in the age of biologics | |
| Aleman et al. | Eosinophilic endotype of asthma | |
| Thomson | Novel approaches to the management of noneosinophilic asthma | |
| Chung | New treatments for severe treatment-resistant asthma: targeting the right patient | |
| Bateman et al. | Development and validation of a novel risk score for asthma exacerbations: the risk score for exacerbations | |
| Moieni et al. | Trait sensitivity to social disconnection enhances pro-inflammatory responses to a randomized controlled trial of endotoxin | |
| Hoang et al. | Epigenome-wide association study of DNA methylation and adult asthma in the Agricultural Lung Health Study | |
| Hekking et al. | Transcriptomic gene signatures associated with persistent airflow limitation in patients with severe asthma | |
| Silkoff et al. | Identification of airway mucosal type 2 inflammation by using clinical biomarkers in asthmatic patients | |
| Walsh et al. | Exacerbation risk in severe asthma is stratified by inflammatory phenotype using longitudinal measures of sputum eosinophils | |
| Fingleton et al. | Serum periostin in obstructive airways disease | |
| Soma et al. | Implication of fraction of exhaled nitric oxide and blood eosinophil count in severe asthma | |
| Su et al. | Longitudinal analysis of sarcoidosis blood transcriptomic signatures and disease outcomes | |
| Dunn et al. | Impact of age and sex on response to asthma therapy | |
| Rabinovitch et al. | Predictors of asthma control and lung function responsiveness to step 3 therapy in children with uncontrolled asthma | |
| Chung | Diagnosis and management of severe asthma | |
| Damera et al. | A sputum proteomic signature that associates with increased IL-1β levels and bacterial exacerbations of COPD | |
| Fricker et al. | Relationship of sputum mast cells with clinical and inflammatory characteristics of asthma | |
| Berger et al. | Distal airway dysfunction identifies pulmonary inflammation in asymptomatic smokers | |
| Suzukawa et al. | Baseline serum CXCL10 and IL-12 levels may predict severe asthmatics' responsiveness to omalizumab | |
| Huang et al. | Diagnostic and therapeutic value of Hsa_circ_0002594 for T helper 2-mediated allergic asthma |